These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39237679)

  • 1. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Yanagisawa T; Parizi MK; Laukhtina E; Klemm J; Fazekas T; Mori K; Kimura S; Briganti A; Ploussard G; Karakiewicz PI; Miki J; Kimura T; Rajwa P; Shariat SF
    Prostate Cancer Prostatic Dis; 2024 Sep; ():. PubMed ID: 39237679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    El-Taji O; Taktak S; Jones C; Brown M; Clarke N; Sachdeva A
    JAMA Oncol; 2024 Jul; 10(7):874-884. PubMed ID: 38842801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Fervaha G; Spratt DE; Sun Y; Kishan AU; Loblaw A; Malone S; Ong M; Saad F; Wallis CJD; Morgan SC
    Eur Urol; 2024 Jul; 86(1):10-17. PubMed ID: 38570246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
    Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
    Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS).
    Liu Y; Zhang HM; Jiang Y; Wen Z; Bao EH; Huang J; Wang CJ; Chen CX; Wang JH; Yang XS
    Clin Genitourin Cancer; 2023 Oct; 21(5):594-601.e2. PubMed ID: 37482524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
    Swami U; Xie B; Young C; Ramaswamy K; El-Chaar N; Gao W; Yang H; Wang Y; Mucha L
    Prostate; 2024 Nov; 84(15):1387-1397. PubMed ID: 39162127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
    Rizzo A; Merler S; Sorgentoni G; Oderda M; Mollica V; Gadaleta-Caldarola G; Santoni M; Massari F
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1237-1243. PubMed ID: 34407702
    [No Abstract]   [Full Text] [Related]  

  • 11. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
    Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Philippou YA; Kuntz GM; Konety BR; Gupta S; Lamb AD; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012816. PubMed ID: 30320443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
    Aziz MK; Molony D; Monlezun D; Holder T; Brunckhorst O; Higgason N; Roland J; Magill R; Fatakdawala M; Iacobucci A; Mody-Bailey N; Owen C; Zarker A; Thames E; Swaby J; Xiao D; Choi L; Desai S; Galan J; Deng B; Hartshorne T; Nichols A; Zhang A; Imber J; Song J; Jones W; Rivas A; Sanchez D; Guhan M; Gandaglia G; Ranganath S; Jacob J; Howell S; Plana J; van den Bergh R; Roberts M; Sommer SG; Oldenburg J; Ploussard G; Tilki D; Schoots I; Briers E; Stranne J; Rouviere O; van Oort I; Oprea-Lager D; De Santis M; Cornford P; ; Koutroumpakis E; Ziaolhagh A; Ali A; Wamique Yusuf S; Iliescu C; Canfield S
    Eur Urol; 2025 Jan; 87(1):15-26. PubMed ID: 39299896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
    Cao B; Kim M; Reizine NM; Moreira DM
    Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.